Takeda, Japan's biggest drugmaker, said on Friday that U.S. health authorities have not been able to complete a review of alogliptin or SYR-322, which is critical to Takeda's mainstay diabetes business as it is expected to be the main replacement for its best-selling Actos.
Actos generates almost 30 percent of Takeda's sales but loses U.S. patent protection in 2011.
More
1 comment:
Maybe it has more to do with the serious problems caused by sitagliptin - i.e., severe joint pain experienced by many consumers.
Post a Comment